USFDA1 April 2026 at 06:45 am
Marksans Pharma Receives USFDA Approval for Benzonatate Capsules
AI Summary
Marksans Pharma Limited has received USFDA approval for Benzonatate Capsules USP, 100 mg & 200 mg (Rx). The product is bioequivalent and therapeutically equivalent to Pfizer Inc.'s Tessalon Capsules, 100 mg and 200 mg. Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract, reducing the cough reflex and relieving persistent cough, bronchitis, pneumonia or other lung infections.
Key Highlights
- Marksans Pharma Limited receives USFDA approval for Benzonatate Capsules USP, 100 mg & 200 mg (Rx)
- The product is bioequivalent and therapeutically equivalent to Pfizer Inc.'s Tessalon Capsules, 100 mg and 200 mg
- Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract
- It reduces the cough reflex and relieves persistent cough, bronchitis, pneumonia or other lung infections
MARKSANSPharmaceuticals
MARKSANS PHARMA LTD.Price Impact